Sage Journals: Discover world-class research

Abstract

The highly practical acetylation of free nucleosides is achieved using acetic anhydride/acetic acid as a reusable solvent and acetylating regent. A series of nucleosides, including ribosyl, deoxyribosyl, arabinosyl, acyclic and pyranosyl, and many clinical drugs were acetylated efficiently, even on large scale (200 g).

Keywords

acetylation hydroxy group protection late-stage modification nucleosides reusable solvent

Introduction

In recent years, modified nucleosides have become of significant interest due to their intriguing biological and pharmacological properties.^1,2 In the context of the outbreak of COVID-19, nucleoside drugs have once again attracted the attention of scientists, and remdesivir,³ molnupiravir,³ azvudine⁴ have been used clinically for the treatment of COVID-19. The late-stage modification of nucleosides is an important method for obtaining a variety of nucleoside drugs.⁵ However, the direct modification of free nucleosides is often inhibited or there is a lack of selectivity due to the presence of hydroxy groups on the sugar rings.^6,7 As a result, the development of methods for the protection of hydroxy groups has been the subject of intense research.⁸ In addition, the presence of an acetoxy group in pharmaceuticals often modulates their solubility and pharmacokinetics, while optimizing their pharmacological and physiochemical properties.⁹ The acetylation of hydroxy groups is often a powerful and low-cost approach, which is routinely carried out by reacting free nucleosides with acetic anhydride in the presence of a catalyst, for example, DMAP (4-dimethylaminopyridine), which is the most widely used catalyst for this purpose.¹⁰ In factories, the most common way to produce 1,2,3,5-tetraacetyl-β-d-ribose (1) is through the cleavage of glycosidic bonds of 2’,3’,5’-tri-O-acetylinosine (2a) catalyzed by boric acid.¹¹ However, we found that the residual DMAP in 2a could inhibit the reaction or reduce the yield of compound 1 (Scheme 1). Therefore, more steps have to be taken to remove DMAP and to improve the purity of 2a.

Scheme 1.

The synthesis of 1,2,3,5-tetraacetyl-β-d-ribose (1) from 2’,3’,5’-tri-O-acetylinosine (2a) catalyzed by boric acid.

This finding prompted us to improve the acetylation of the hydroxy groups of nucleosides, avoiding the existing deficiencies. Following on from our previous research on nucleosides,^12–15 we herein report the practical acetylation of the hydroxy groups of nucleosides without an additional catalyst by using acetic anhydride/acetic acid as a reusable solvent.

We began our studies by using inosine (3a) as a model substrate to optimize the reaction conditions (Scheme 2, Table 1). Under the conditions of a previous report,¹⁶ we found that by using molecular sieves as the catalyst and acetic anhydride as the solvent, product 2a was obtained in 91% yield. Although molecular sieves were better than DMAP, pure acetic anhydride was used as the solvent, which increased the production cost. We speculated whether the acetic anhydride recovered during the work-up process, and containing some acetic acid generated during the reaction, could be reused. To our delight, the yield of 2a was 63% when recovered acetic anhydride (85% content) was used as the solvent at 60 ^oC for 4 h (entry 1). The C-N glycosidic bond of 2a could be successfully cleaved by boric acid to produce 1. The yield of 2a increased when the reaction temperature was raised, and 80 ^oC proved to be the better choice (entries 2 and 3). Screening of the reaction time showed that 6 h was the best choice (entries 4 and 5). The yield of 2a was maintained, when using recovered acetic anhydride (following a second run); in this case, the content of acetic anhydride was 71% (entry 6). Further research showed that the solvent could be recycled at least 4 times, and that the content of acetic anhydride was 41% (entry 7). When the content of acetic anhydride was less than 41%, the yield was reduced to 80% (entry 8). The recovered solvent could also be reused by adding acetic anhydride to increase the content of acetic anhydride above 42%. In addition, the significance of this discovery was that impure acetic anhydride recovered from other reactions could also be used as a solvent, which can significantly reduce costs.

Scheme 2.

The acetylation of inosine (3a).

Table 1.

Optimization of the reaction conditions for the acetylation of inosine (3a).^a

Entry	Temp (^oC)	Ac₂O content of Ac₂O/AcOH	Time (h)	Yield (%)
1	60	85%	4	63
2	70	85%	4	77
3	80	85%	4	85
4	80	85%	6	92
5	80	85%	8	91
6^b	80	71%	6	91
7^c	80	41%	6	90
8^d	80	29%	6	80

Reaction conditions: 3a (1 mmol), solvent (2 mL); isolated yields are given.

The solvent was reused 2 times.

The solvent was reused 4 times.

The solvent was reused 5 times.

Under the optimized reaction conditions and with 60% acetic anhydride/acetic acid as the solvent, a series of free nucleosides was subjected to the acetylation reaction under the optimized conditions (Scheme 3). To our delight, all the hydroxy groups were acetylated to afford satisfactory yields of products (2a-h, 86%–93%). This system could tolerate a vareity of substitutes on purine rings such as Cl, F, NH₂ and OH and the substitutes had little impact on the yields (2b vs 2d, 2e vs 2f). This catalytic system proved highly efficient for the ribosides 2a-d. It was worth mentioning that acetylation occurred exclusively on the hydroxy groups of the sugar, and the probable reason was that the amino groups were protonated under the reaction conditions.

Scheme 3.

The acetylation of a series of free nucleosides.

Subsequently, a variety of nucleosides bearing other glycals or nucleobases (4a-4g) were then studied (Scheme 4). Acyclic, pyranosyl and pyrimidine nucleosides all reacted well to give the corresponding acetylated products 5a-g in good to high yields of 86%–94%. Famciclovir, an effective oral prodrug of the antiviral penciclovir for the treatment of herpes zoster was synthesized in 88% yield. Three pyrimidine nucleosides also reacted smoothly to afford products 5f-h in high yields. Xuriden (5h) is used to treat ultra-orphan indication hereditary whey aciduria. These results showed that this catalytic system tolerates various substituents.

Scheme 4.

The acetylation of free nucleosides bearing other glycals or nucleobases.

Next, reactions on large scale demonstrated the robustness and preparative scale utility of this process. 2’,3’,5’-tri-O-Acetylinosine (2a) could be obtained successfully on 200 g scale in a comparable yield of 90%. More importantly, the product could be purified by recrystallization, thereby avoiding chromatography and/or a lengthy work-up process, which makes this route attractive for industrial applications.

Conclusion

In summary, we have developed a highly practical and improved process for the acetylation of the hydroxy groups of nucleosides. The acetic anhydride could be reused 4–5 times. A series of nucleosides including ribosyl, deoxyribosyl, arabinosyl, acyclic and pyranosyl worked well. What is more, the catalytic system tolerated different functional groups including F, Cl, and NH₂. Importantly, the drugs nebularine, clofarabine, fludarabine, vidarabine, famciclovir and xuriden could be successfully acetylated, providing a simple method for the late-stage modification of these drugs. In addition, the reaction scale could be increased to 200 g, which is important for industrial applications. Further investigations on this reaction are underway in our laboratory.

Experimental

General

Melting points were recorded with a X-5 micro melting point apparatus and uncorrected (Beijing Taike Instruments Co., Ltd.). ¹H and ¹³C NMR spectra were recorded on a Bruker AC 400 spectrometer (Bruker, Billerica, MA, USA) as CDCl₃ or DMSO-d₆ solutions. Chemical shifts are expressed in parts per million (δ) downfield from the internal standard tetramethylsilane. Multiplicities are reported as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and dd (doublet of doublets), and coupling constants (J) are given in hertz (Hz). Mass spectra were obtained on a Waters Q-Tof MicroTM spectrometer (Waters Synapt).

General procedure

Free nucleoside (1 mmol) was added to 60% acetic anhydride-acetic acid (2 mL). The resulting mixture was heated to 80 ^oC and kept at this temperature for 4–8 h. Upon completion of the reaction, the solvent was removed under vacuum. The product was purified by column chromatography on silica gel (eluent: ethyl acetate/petroleum ether) to give the pure product.

Large-scale procedure (200 g scale) for the synthesis of 2a

Inosine (200 g, 746 mmol) was added to 60% acetic anhydride-acetic acid (800 mL). The resulting mixture was stirred and heated at 80 ^oC in an oil bath for 10 h. Upon completion of the reaction, the solvent was recovered under vacuum and the residual solvent was co-evaporated with ethanol (50 mL). The oily residue was recrystallized from H₂O to give the pure product (90% yield).

(2R,3R,4R,5R)-2-(Acetoxymethyl)-5-(6-oxo-1H-purin-9(6H)-yl)tetrahydrofuran-3,4-Diyl diacetate (2a): Yield: 0.362 g (92%). White solid, m.p. 240–242 ^oC (Lit.¹⁷ 239–243 ^oC). ¹H NMR (400 MHz, DMSO-d₆): δ = 10.73 (br s, 1H, NH), 8.31 (s, 1H, 2-H), 7.94 (s, 1H, 8-H), 6.00 (d, J = 6.0 Hz, 1H, 1’-H), 5.80 (t, J = 6.0 Hz, 1H, 2’-H), 5.50 (t, J = 4.4 Hz, 1H, 4’-H), 4.40–4.24 (m, 3H, 3’ and 5’-H), 2.12 (s, 3H, OAc), 2.05 (s, 3H, OAc), 2.04 (s, 3H, OAc). ¹³C NMR (100 MHz, DMSO-d₆): δ = 170.6 (OAc), 169.9 (OAc), 169.7 (OAc), 157.1 (6-C), 154.4 (4-C), 151.6 (2-C), 136.1 (8-C), 117.3 (5-C), 84.9 (1’-C), 80.0 (2’-C), 72.5 (4’-C), 70.8 (3’-C), 63.6 (5’-C), 21.0 (OAc), 20.9 (OAc), 20.7 (OAc). HRMS (ESI): m/z [M + H]⁺ calcd for C₁₆H₁₉N₄O₈: 395.1197; found: 395.1199.

(2R,3R,4R,5R)-2-(Acetoxymethyl)-5-(6-amino-9H-purin-9-yl)tetrahydrofuran-3,4-diyl Diacetate (2b): Yield: 0.357 g (91%). White solid, m.p. 174–176 ^oC (Lit.¹⁸ 174–175 ^oC). ¹H NMR (400 MHz, CDCl₃): δ = 8.33 (s, 1H, 2-H), 7.95 (s, 1H, 8-H), 6.18 (d, J = 5.6 Hz, 1H, 1’-H), 6.14 (br s, 2H, NH₂), 5.92 (t, J = 5.6 Hz, 1H, 2’-H), 5.66 (t, J = 4.8, 1H, 4’-H), 4.45–4.33 (m, 3H, 3’ and 5’-H), 2.12 (s, 3H, OAc), 2.09 (s, 3H, OAc), 2.06 (s, 3H, OAc). ¹³C NMR (100 MHz, CDCl₃): δ = 170.3 (OAc), 169.5 (OAc), 169.3 (OAc), 155.5 (6-C), 153.0 (4-C), 149.7 (2-C), 138.8 (8-C), 120.0 (5-C), 86.2 (1’-C), 80.2 (2’-C), 73.1 (4’-C), 70.6 (3’-C), 63.1 (5’-C), 20.7 (OAc), 20.5 (OAc), 20.3 (OAc). HRMS (ESI): m/z [M + H]⁺ calcd for C₁₆H₂₀N₅O₇: 394.1357; found: 394.1357.

(2R,3R,4R,5R)-2-(Acetoxymethyl)-5-(9H-purin-9-yl)tetrahydrofuran-3,4-diyl Diacetate (2c): Yield: 0.351 g (93%). Colorless oil, (Lit.¹² Oil). ¹H NMR (400 MHz, CDCl₃): δ = 9.17 (s, 1H, 6-H), 9.00 (s, 1H, 2-H), 8.27 (s, 1H, 8-H), 6.26 (d, J = 5.2 Hz, 1H, 1’-H), 5.97 (t, J = 5.2 Hz, 1H, 2’-H), 5.67 (t, J = 4.8, 1H, 4’-H), 4.46–4.35 (m, 3H, 3’ and 5’-H), 2.15 (s, 3H, OAc), 2.11 (s, 3H, OAc), 2.07 (s, 3H, OAc). ¹³C NMR (100 MHz, CDCl₃): δ = 170.3 (OAc), 169.5 (OAc), 169.3 (OAc), 152.7 (6-C), 150.9 (4-C), 148.9 (2-C), 143.7 (8-C), 134.6 (5-C), 86.4 (1’-C), 80.3 (2’-C), 73.0 (4’-C), 70.5 (3’-C), 62.9 (5’-C), 20.7 (OAc), 20.5 (OAc), 20.3 (OAc). HRMS (ESI): m/z [M + H]⁺ calcd for C₁₆H₁₉N₄O₇: 379.1248; found: 379.1246.

(2R,3R,4R,5R)-2-(Acetoxymethyl)-5-(6-amino-2-chloro-9H-purin-9-yl)tetrahydrofuran-3,4-diyl Diacetate (2d): Yield: 0.393 g (93%). White solid, m.p. 150–152 ^oC. (Lit.¹⁹ 151–152 ^oC). ¹H NMR (400 MHz, CDCl₃): δ = 8.26 (s, 1H, 8-H), 6.21 (d, J = 5.6 Hz, 1H, 1’-H), 6.14 (br s, 2H, NH₂), 5.78 (t, J = 5.6, 1H, 2’-H), 5.56 (t, J = 4.8, 1H, 4’-H), 4.44–4.35 (m, 3H, 3’ and 5’-H), 2.11 (s, 3H, OAc), 2.08 (s, 3H, OAc), 2.03 (s, 3H, OAc). ¹³C NMR (100 MHz, CDCl₃): δ = 170.4 (OAc), 169.7 (OAc), 169.5 (OAc), 152.3 (6-C), 154.5 (4-C), 150.7 (2-C), 138.8 (8-C), 118.6 (5-C), 85.9 (1’-C), 80.5 (2’-C), 73.3 (4’-C), 70.7 (3’-C), 63.1 (5’-C), 20.8 (OAc), 20.6 (OAc), 20.5 (OAc). HRMS (ESI): m/z [M + H]⁺ calcd for C₁₆H₁₉ClN₅O₇: 428.0968; found: 428.0964.

(2R,3R,4S,5R)-2-(Acetoxymethyl)-5-(6-amino-9H-purin-9-yl)tetrahydrofuran-3,4-diyl Diacetate (2e): Yield: 0.349 g (89%). White solid, m.p. 128–130 ^oC. (Lit.²⁰ 128.5–129 ^oC). ¹H NMR (400 MHz, CDCl₃): δ = 8.35 (s, 1H, 2-H), 8.00 (s, 1H, 8-H), 6.58 (d, J = 4.8 Hz, 1H, 1’-H), 5.96 (br s, 2H, NH₂), 5.51 (q, J = 1.2 Hz, 1H, 2’-H), 5.43 (t, J = 4.0 Hz, 1H, 4’-H), 4.47–4.45 (m, 2H, 5’-H), 4.27 (q, J = 4.8, 1H, 3’-H), 2.15 (s, 3H, OAc), 2.12 (s, 3H, OAc), 1.90 (s, 3H, OAc). ¹³C NMR (100 MHz, CDCl₃): δ = 170.3 (OAc), 169.4 (OAc), 168.5 (OAc), 151.3 (6-C), 151.2 (4-C), 146.7 (2-C), 145.5 (8-C), 133.1 (5-C), 83.0 (1’-C), 80.0 (2’-C), 75.4 (4’-C), 74.6 (3’-C), 62.6 (5’-C), 20.5 (OAc), 20.4 (OAc), 19.9 (OAc). HRMS (ESI): m/z [M + H]⁺ calcd for C₁₆H₂₀N₅O₇: 394.1357; found: 394.1357.

((2R,3R,4S,5R)-3-Acetoxy-5-(6-amino-2-chloro-9H-purin-9-yl)-4-fluorotetrahydrofuran-2-yl)methyl Acetate (2f): Yield: 0.333 g (86%). White solid, m.p. 190–192 ^oC. (Lit.²¹ 190–192 ^oC). ¹H NMR (CDCl₃, 400 MHz): δ = 8.08 (s, 1H, 2-H), 6.88 (br s, 2H, NH₂), 6.47 (d, J_H-F = 22.4 Hz, 1H, 1’-H), 5.35 (d, J = 16 Hz, 1H, 4’-H), 5.19 (d, J_H-F = 50 Hz, 1H, 2’-H), 4.48–4.39 (m, 2H, 3’ and 5’-H), 4.27 (s, 1H, OAc), 2.17 (s, 3H, OAc), 2.10 (s, 3H, OAc). ¹³C NMR (DMSO-d₆, 100 MHz): δ = 170.1 (OAc), 169.6 (OAc), 156.8 (6-C), 153.4 (4-C), 150.2 (2-C), 140.1 (8-C), 117.3 (5-C), 93.5 (d, J = 190.6 Hz, 2’-C), 81.8 (d, J = 16.6 Hz, 1’-C), 78.1 (d, J = 2.9 Hz, 4’-C), 75.3 (d, J = 27.5 Hz, 3’-C), 62.9 (5’-C), 20.5 (OAc), 20.4 (OAc). HRMS (ESI): m/z [M + Na]⁺ calcd for C₁₄H₁₅ClFN₅NaO₅: 410.0638; found: 410.0640.

(2R,3R,4S,5R)-2-(Acetoxymethyl)-5-(6-amino-2-fluoro-9H-purin-9-yl)tetrahydrofuran-3,4-diyl Diacetate (2g): Yield: 0.353 g (86%). White solid, m.p. 182–184 ^oC. (Lit.²² 182–183 ^oC). ¹H NMR (400 MHz, CDCl₃): δ = 8.27 (s, 1H, 2-H), 6.56 (d, J = 4.8 Hz, 1H, 1’-H), 6.04 (br s, 2H, NH₂), 5.47 (q, J = 0.8 Hz, 1H, 2’-H), 5.34 (t, J = 3.2 Hz, 1H, 4’-H), 4.43 (q, J = 4.4 Hz, 2H, 5’-H), 4.27–4.23 (m, 1H, 3’-H), 2.12 (s, 3H, OAc), 2.08 (s, 3H, OAc), 1.86 (s, 3H, OAc). ¹³C NMR (100 MHz, CDCl₃): δ = 170.5 (OAc), 169.6 (OAc), 168.5 (OAc), 159.9 (d, J_C-F = 215.6 Hz, 2-C), 153.3 (d, J_C-F = 16.2 Hz, 6-C), 151.2 (d, J_C-F = 15.5 Hz, 4-C), 144.9 (d, J_C-F = 2.8 Hz, 8-C), 132.5 (d, J_C-F = 4.2 Hz, 5-C), 83.1 (1’-C), 80.3 (2’-C), 75.7 (4’-C), 74.7 (3’-C), 62.7 (5’-C), 20.7 (OAc), 20.6 (OAc), 20.2 (OAc). HRMS (ESI): m/z [M + H]⁺ calcd for C₁₆H₁₉FN₅O₇: 412.1263; found: 412.1267.

((2R,3S,5R)-3-Acetoxy-5-(6-amino-9H-purin-9-yl)tetrahydrofuran-2-yl)methyl Acetate (2h): Yield: 0.295 g (88%). White solid, m.p. 152–154 ^oC. (Lit.²³ 153–154 ^oC). ¹H NMR (400 MHz, CDCl₃): δ = 8.96 (s, 1H, 2-H), 8.34 (s, 1H, 8-H), 6.48 (t, J = 6.8 Hz, 1H, 1’-H), 6.16 (br s, 2H, NH₂), 5.40 (d, J = 1.5 Hz, 1H, 4’-H), 4.35–4.28 (m, 3H, 3’ and 5’-H), 3.02–2.95 (m, 1H, 2’-H), 2.65–2.60 (m, 1H, 2’-H), 2.07 (s, 3H, OAc), 2.00 (s, 3H, OAc). ¹³C NMR (100 MHz, CDCl₃): δ = 170.2 (OAc), 170.1 (OAc), 151.8 (6-C), 150.9 (4-C), 147.8 (2-C), 144.1 (8-C), 134.2 (5-C), 84.6 (1’-C), 82.6 (4’-C), 74.1 (3’-C), 63.5 (5’-C), 37.1 (2’-C), 20.7 (OAc), 20.6 (OAc). HRMS (ESI): m/z [M + H]⁺ calcd for C₁₄H₁₈N₅O₅: 336.1302; found: 336.1302.

2-((6-Chloro-9H-purin-9-yl)methoxy)ethyl Acetate (5a): Yield: 0.253 g (94%). White solid, m.p. 96–98 ^oC. (Lit.²⁴ 96 ^oC). ¹H NMR (400 MHz, CDCl₃): δ = 8.77 (s, 1H, 2-H), 8.29 (s, 1H, 8-H), 5.72 (s, 2H, -CH₂-), 4.18 (t, J = 4.8 Hz, 2H, -CH₂-CH₂-), 3.77 (t, J = 4.8 Hz, 2H, -CH₂-CH₂-), 2.01 (s, 3H, OAc). ¹³C NMR (100 MHz, DMSO-d₆): δ = 170.3 (OAc), 156.0 (6-C), 152.9 (4-C), 149.7 (2-C), 141.2 (8-C), 118.5 (5-C), 72.0 (-CH₂-), 66.9 (-CH₂-CH₂-), 62.8 (-CH₂-CH₂-), 20.5 (OAc). HRMS (ESI): m/z [M + H]⁺ calcd for C₁₀H₁₂ClN₄O₃: 271.0592; found: 271.0596.

2-((6-Amino-9H-purin-9-yl)methoxy)ethyl Acetate (5b): Yield: 0.228 g (91%). White solid, m.p. 156–158 ^oC. (Lit.²⁵ 156–158 ^oC). ¹H NMR (400 MHz, DMSO-d₆): δ = 8.29 (s, 1H, 2-H), 8.17 (s, 1H, 8-H), 7.33 (br s, 2H, NH₂), 5.56 (s, 2H, -CH₂-), 4.06 (t, J = 4.4 Hz, 2H, -CH₂-CH₂-), 3.70 (t, J = 4.4 Hz, 2H, -CH₂-CH₂-), 1.92 (s, 3H, OAc). ¹³C NMR (100 MHz, CDCl₃): δ = 170.7 (OAc), 159.6 (6-C), 152.7 (4-C), 150.8 (2-C), 143.6 (8-C), 132.7 (5-C), 72.6 (-CH₂-), 67.8 (-CH₂-CH₂-), 62.8 (-CH₂-CH₂-), 19.5 (OAc). HRMS (ESI): m/z [M + H]⁺calcd for C₁₀H₁₄N₅O₃: 252.1091; found: 252.1095.

2-(2-(2-Amino-9H-purin-9-yl)ethyl)propane-1,3-diyl Diacetate (Famciclovir) (5c): Yield: 0.282 g (88%). White solid, m.p. 100–102 ^oC. (Lit.²⁶ 100–102 ^oC). ¹H NMR (400 MHz, DMSO-d₆): δ = 8.57 (s, 1H, 6-H), 8.09 (s, 1H, 8-H), 6.49 (br s, 2H, NH₂), 4.14 (t, J = 7.2 Hz, 2H, 1’-H), 4.04 (d, J = 5.6 Hz, 4H, 4’ and 5’-H), 1.99 (s, 6H, OAc), 1.95–1.84 (m, 3H, 2’ and 3’-H). ¹³C NMR (100 MHz, DMSO-d₆): δ = 170.8 (OAc), 160.9 (OAc), 153.4 (6-C), 149.5 (4-C), 143.1 (2-C), 127.4 (8-C), 63.9 (4’ and 5’-C), 35.0 (1’-C), 28.3 (3’-C), 21.1 (OAc). HRMS (ESI): m/z [M + H]⁺calcd for C₁₄H₂₀N₅O₄: 322.1510; found: 322.1516.

(2R,3R,4R,5R,6R)-2-(Acetoxymethyl)-6-(6-amino-9H-purin-9-yl)tetrahydro-2H-pyran-3,4,5-triyl Triacetate (5d): Yield: 0.454 g (94%). White solid, m.p. 160–162 ^oC. (Lit.²⁷ 163 ^oC). ¹H NMR (400 MHz, CDCl₃): δ = 8.74 (s, 1H, 2-H), 8.30 (s, 1H, 8-H), 6.00 (d, J = 9.6 Hz, 1H, 1’-H), 5.65 (t, J = 9.6 Hz, 1H, 3’-H), 5.48 (t, J = 9.6 Hz, 1H, 2’-H), 5.31 (t, J = 9.6 Hz, 1H, 4’-H), 4.38–4.28 (m, 1H, 5’-H), 4.17–4.13 (m, 1H, 6’-H), 4.07–4.03 (m, 1H, 6’-H), 2.08 (s, 1H, OAc), 2.07 (s, 1H, OAc), 2.03 (s, 1H, OAc), 1.73 (s, 1H, OAc). ¹³C NMR (100 MHz, CDCl₃) δ 170.5 (OAc), 169.9 (OAc), 169.4 (OAc), 169.0 (OAc), 153.1 (6-C), 151.3 (4-C), 149.2 (2-C), 142.9 (8-C), 133.8 (5-C), 80.3 (1’-C), 75.2 (5’-C), 72.8 (4’-C), 70.2 (3’-C), 67.7 (2’-C), 61.5 (6’-C), 20.7 (OAc), 20.6 (OAc), 20.5 (OAc), 20.1 (OAc). HRMS (ESI): m/z [M + H]⁺calcd for C₁₉H₂₂ClN₄O₉: 485.1070; found: 485.1070.

(2R,3R,4R,5R,6R)-2-(Acetoxymethyl)-6-(6-amino-9H-purin-9-yl)tetrahydro-2H-pyran-3,4,5-triyl Triacetate (5e): Yield: 0.399 g (86%). White solid, m.p. 130–132 ^oC. (Lit.²⁸ 132 ^oC). ¹H NMR (400 MHz, CDCl₃): δ = 8.79 (s, 1H, 2-H), 8.33 (s, 1H, 8-H), 6.81 (br s, 2H, NH₂), 5.97 (d, J = 9.6 Hz, 1H, 1’-H), 5.68 (t, J = 9.6 Hz, 1H, 3’-H), 5.48 (t, J = 9.6 Hz, 1H, 2’-H), 5.31 (t, J = 9.6 Hz, 1H, 4’-H), 4.33–4.28 (m, 1H, 6’-H), 4.18 (d, J = 12.4 Hz, 1H, 5’-H), 4.07–4.04 (m, 1H, 6’-H), 2.09 (s, 3H, OAc), 2.08 (s, 3H, OAc), 2.05 (s, 3H, OAc), 1.78 (s, 3H, OAc). ¹³C NMR (100 MHz, CDCl₃): δ = 170.4 (OAc), 169.9 (OAc), 169.3 (OAc), 169.0 (OAc), 152.5 (6-C), 151.7 (4-C), 151.6 (2-C), 142.9 (8-C), 131.6 (5-C), 80.9 (1’-C), 75.3 (5’-C), 72.8 (4’-C), 70.2 (3’-C), 67.7 (2’-C), 61.5 (6’-C), 20.7 (OAc), 20.6 (OAc), 20.5 (OAc), 20.1 (OAc). HRMS (ESI): m/z [M + H]⁺calcd for C₁₉H₂₄N₅O₉: 466.1569; found: 466.1573.

((2R,3S,5R)-3-Acetoxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl Acetate (5f): Yield: 0.293 g (90%). White solid, m.p. 126–128 ^oC. (Lit.²⁹ 126–127 ^oC). ¹H NMR (400 MHz, CDCl₃): δ = 9.49 (s, 1H, NH), 6.34 (t, J = 7.6 Hz, 1H, 1’-H), 5.23 (d, J = 6.0 Hz, 1H, 4’-H), 4.40–4.32 (m, 2H, 5’-H), 4.25 (s, 1H, 6-H), 2.50–2.45 (m, 1H, 5’-H), 2.21–2.15 (m, 1H, 5’-H), 2.13 (s, 3H, OAc), 2.12 (s, 3H, OAc), 1.95 (s, 3H, 5-CH₃). ¹³C NMR (100 MHz, CDCl₃): δ = 170.4 (OAc), 169.8 (OAc), 163.0 (4-C), 149.4 (2-C), 136.0 (6-C), 121.0 (5-C), 91.8 (1’-C), 78.7 (4’-C), 70.0 (3’-C), 62.8 (5’-C), 35.3 (2’-C), 20.8 (OAc), 20.4 (OAc), 13.1 (5-CH₃). HRMS (ESI): m/z [M + H]⁺ calcd for C₁₄H₁₉N₂O₇: 327.1187; found: 327.1189.

(2R,3R,4R,5R)-2-(Acetoxymethyl)-5-(5-chloro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3,4-diyl Diacetate (5g): Yield: 0.375 g (93%). Oil, (Lit.³⁰ m.p. 54 ^oC). ¹H NMR (400 MHz, CDCl₃): δ = 9.71 (s, 1H, NH), 7.88 (s, 1H, 6-H), 6.05 (d, J = 4.4 Hz, 1H, 1’-H), 5.34 (t, J = 4.0 Hz, 2H, 2’ and 4’-H), 4.38–4.31 (m, 3H, 3’ and 5’-H), 2.21 (s, 3H, OAc), 2.10 (s, 3H, OAc), 2.08 (s, 3H, OAc). ¹³C NMR (100 MHz, CDCl₃): δ = 170.2 (OAc), 169.7 (OAc), 159.9 (4-C), 150.1 (2-C), 143.9 (6-C), 107.5 (5-C), 87.1 (1’-C), 79.8 (4’-C), 72.3 (2’-C), 70.3 (3’-C), 63.5 (5’-C), 20.8 (OAc), 20.6 (OAc), 20.5 (OAc). HRMS (ESI): m/z [M + H]⁺calcd for C₁₅H₁₈ClN₂O₉: 405.0695; found: 405.0699.

Xuriden (5h): Yield: 0.333 g (90%). White solid, m.p. 127–128 ^oC. (Lit.³¹ 127–130 ^oC). ¹H NMR (400 MHz, CDCl₃): δ = 9.68 (s, 1H, NH), 7.40 (d, J = 8.4 Hz, 1H, 5-H), 6.04 (d, J = 3.6 Hz, 1H, 1’-H), 5.79 (d, J = 7.2 Hz, 1H, 2’-H), 5.32 (s, 2H, 3’ and 4’-H), 4.34 (s, 3H, 5’-H and 6-H), 2.13 (s, 3H, OAc), 2.12 (s, 3H, OAc), 2.09 (s, 3H, OAc). ¹³C NMR (100 MHz, CDCl₃): δ = 170.2 (OAc), 170.1 (OAc), 169.7 (OAc), 162.8 (4-C), 150.3 (2-C), 139.3 (6-C), 103.4 (5-C), 87.5 (1’-C), 80.0 (4’-C), 72.7 (2’-C), 70.2 (3’-C), 63.2 (5’-C), 20.8 (OAc), 20.5 (OAc), 20.4 (OAc). HRMS (ESI): m/z [M + H]⁺calcd for C₁₅H₁₉N₂O₉: 371.1085; found: 371.1089.

Supplemental Material

sj-pdf-1-chl-10.1177_17475198221115020 – Supplemental material for The practical acetylation of nucleosides using acetic anhydride/acetic acid as a reusable solvent

Supplemental material, sj-pdf-1-chl-10.1177_17475198221115020 for The practical acetylation of nucleosides using acetic anhydride/acetic acid as a reusable solvent by Ran Xia, Chao Xia, Ying-Xing Yang, Li-Jie Liu, Lei-Shan Chen and Li-Ping Sun in Journal of Chemical Research

Footnotes

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: We thank the Key Scientific and Technical Projects of Henan Province (212102310333, 222102110403), the Training Plan for Young Key Teachers in Universities of Henan Province (202GGJS248), the Key Scientific and Technical Projects of Xinxiang City (GG2021016) and the Major Scientific and Technical Projects of Xinxiang City (21ZD008) for financial support.

ORCID iDs

Ran Xia

Li-Ping Sun

Supplemental material

Supplemental material for this article is available online.

References

Miller

GJ.

Science 2020; 369: 623.

Chmela

Green

, et al. Nature 2020; 582: 60–66.

Chang

Sig Transduct Target Ther 2020; 5: 236.

Halford

C&EN 2021; 99: 44–45.

Sebastian

Satishkumar

Pradhan

, et al. J Org Chem 2022; 87: 18–39.

Bahrami

Franco

Mar Drugs 2016; 14: 147.

Perkins

Shurtleff

Johnson

, et al. ACS Med Chem Lett 2021; 12: 662666.

Tranová

Stýskala

J Org Chem 2021; 86(19): 13265–13275.

Köckinger

Hanselmann

Roberge

, et al. Green Chem 2021; 23: 2382–2390.

10.

Hofle

Steglich

Vorbruggen

Angew Chem Int Ed 1978; 17: 569.

11.

Zhang

Mei

, et al. Org Prep Proced Int 2012; 44: 387–391.

12.

Xia

Xie

Niu

, et al. Green Chem 2014; 16: 1077–1081.

13.

Xia

Niu

, et al. Org Lett 2014; 16: 444–447.

14.

Xia

Sun

Yang

, et al. J Chem Res 2015; 39: 335–667.

15.

Xia

Sun

Chen

LS.

J Chem Res 2016; 40: 358–360.

16.

Mandolesi Sá

Meier

. Synlett 2006; 3474.

17.

Francom

Janeba

Shibuya

, et al. J Org Chem 2002; 67: 6788–6796.

18.

Car

Petrović

Tomić

. J Carbohyd Chem 2006; 25: 713–723.

19.

Robins

Uznański

Can J Chem 1981; 59: 2601–2607.

20.

Reist

Calkins

Fisher

, et al. J Org Chem 1968; 33: 1600–1603.

21.

Xia

Guo

Qin

Chin J Org Chem 2014; 34: 1154–1160.

22.

Bauman

Wirsching

RC.

WO 9412514 A1, 1994.

23.

Lodyga-Chruscinska

Oldziej

Sochacka

, et al. J Inorg Biochem 2011; 105: 1212–1219.

24.

Lanver

Schmalz

HG.

Molecules 2005; 10: 508–515.

25.

Robins

Hatfield

PW.

Can J Chem 1982; 60: 547–553.

26.

Kalayanov

Jakša

Scarcia

, et al. Synthesis 2004; 12: 2026–2034.

27.

Blackburn

Johnson

AW.

J Chem Soc 1960; 4347.

28.

Barker

Foll

GE.

J Chem Soc 1957; 3794–3798.

29.

Gilham

Khorana

HG.

J Am Chem Soc 1958; 80: 6212–6222.

30.

Kumar

Malhotra

SV.

Nucleot Nucleic Acids 2009; 28: 821–834.

31.

El-Tayeb

Nicholas

, et al. J Med Chem 2011; 54: 2878–2890.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

4.90 MB

Entry	Temp (^oC)	Ac₂O content of Ac₂O/AcOH	Time (h)	Yield (%)
1	60	85%	4	63
2	70	85%	4	77
3	80	85%	4	85
4	80	85%	6	92
5	80	85%	8	91
6^b	80	71%	6	91
7^c	80	41%	6	90
8^d	80	29%	6	80

Entry	Temp (^oC)	Ac₂O content of Ac₂O/AcOH	Time (h)	Yield (%)
1	60	85%	4	63
2	70	85%	4	77
3	80	85%	4	85
4	80	85%	6	92
5	80	85%	8	91
6^b	80	71%	6	91
7^c	80	41%	6	90
8^d	80	29%	6	80

Entry	Temp (^oC)	Ac₂O content of Ac₂O/AcOH	Time (h)	Yield (%)
1	60	85%	4	63
2	70	85%	4	77
3	80	85%	4	85
4	80	85%	6	92
5	80	85%	8	91
6^b	80	71%	6	91
7^c	80	41%	6	90
8^d	80	29%	6	80